[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-migraine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-migraine":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,38,0,25,[9,42,73,93,134,157,183,214,241,266,291,312,339,361,383,408,436,457,483,504,522,555,580,605,629],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100594382","phase-3-a-clinical-trial-to-evaluate-efficacy-and-safety-of-xeomin-injections-for-preventing-chronic-migraine-100594382",false,"NCT07018713","A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine","A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial With Extension Period to Evaluate the Efficacy and Safety of Xeomin® Injections for the Prevention of Chronic Migraine","MINT-C","Inclusion Criteria:\n\n* Participant has a diagnosis of CM with or without aura according to the International Classification of Headache Disorders Edition 3 criteria for ≥ 12 months and is able to distinguish migraine headaches from all other types of headaches;\n* Participant age \\\u003C 50 years at the time of migraine onset;\n* Participant meeting the following headache and migraine day criteria in each of the 3 months prior to screening: history of ≥ 15 headache days per month and history of ≥ 8 migraine days per month; and\n* During the last 28 days of the screening period, participant experiencing: ≥ 15 headache days and ≥ 8 migraine days that qualify as such per the headache diary.\n\nExclusion Criteria:\n\n* Diagnosis of other primary headache types, except tension-type headache, which is permitted;\n* Diagnosis of aura without headache, migraine with brainstem aura, hemicrania continua, hypnic headache, hemiplegic migraine, retinal migraine, persistent aura without infarction, migraine aura-triggered seizure, or previous migrainous infarction;\n* Diagnosis of secondary headache types, except medication overuse headache, which is permitted;\n* Currently taking \\> 1 prescribed drug for the preventive treatment of migraine;\n* Discontinuation of anti-calcitonin gene-related peptide (CGRP) \u002F anti-CGRP receptor monoclonal antibody treatment less than 5 months prior to screening.","ALL","18 Years",{"count":21,"type":22},780,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","In this clinical trial, participants with chronic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections.\n\nTrial details include:\n\n* Trial duration: 52 to 55 weeks;\n\n  * Screening period: 4 to 5 weeks;\n  * Treatment duration: 4 treatments, each about 12 weeks apart; and\n* Visit frequency: about every 4 weeks, 14 visits in total. The first and last visit and the 4 treatment visits are on-site, the other 8 visits are remote by phone \u002F video call.",[28],"Chronic Migraine","RECRUITING","2026-08-20",{"date":32,"type":33},"2026-08-21","ACTUAL",{"date":35,"type":33},"2025-08-21",{"date":37,"type":22},"2028-03",{"name":39,"class":40},"Merz Therapeutics GmbH","INDUSTRY",110,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100651575","mechanism-based-cervical-rehabilitation-for-chronic-migraine-100651575","NCT07762690","Mechanism-Based Cervical Rehabilitation for Chronic Migraine","Effect of Mechanism-Based Cervical Sensorimotor Rehabilitation on Cervical Muscle Activation, Joint Position Error, and Migraine Burden in Patients With Chronic Migraine: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Male or female adults aged 18-55 years. Diagnosed with chronic migraine according to the International Classification of Headache Disorders, Third Edition (ICHD-3), defined as headache occurring on ≥15 days per month for more than 3 months, with migraine features present on at least 8 days per month.\n\nHistory of migraine for at least 12 months prior to enrolment. Experiencing chronic migraine during the previous three months, confirmed through clinical history and\u002For headache diary.\n\nPresence of cervical sensorimotor impairment, demonstrated by at least one of the following:\n\nIncreased cervical joint position error. Reduced cervical range of motion. Impaired cervical motor control. Neck pain or cervical dysfunction associated with migraine.\n\nExclusion Criteria:\n\n* • Diagnosis of headache disorders other than chronic migraine (e.g., cervicogenic headache, cluster headache, or medication-overuse headache).\n\nPrevious cervical spine surgery, fracture, or significant cervical trauma. Cervical radiculopathy, myelopathy, or severe cervical spine pathology. Neurological disorders other than migraine (e.g., stroke, multiple sclerosis, Parkinson's disease).\n\nVestibular disorders affecting balance or proprioception. Inflammatory or systemic musculoskeletal diseases (e.g., rheumatoid arthritis, ankylosing spondylitis).\n\nPregnancy or breastfeeding. Physiotherapy, chiropractic treatment, acupuncture, or cervical rehabilitation within the previous 3 months.\n\nBotulinum toxin injections or cervical pain interventions within the previous 3-4 months.\n\nChanges in migraine preventive medication within the previous 4 weeks. Skin conditions preventing surface EMG electrode placement. Inability to comply with the study protocol or provide informed consent.",true,"55 Years",{"count":52,"type":22},80,[54],"NA","To investigate the effectiveness of mechanism-based cervical sensorimotor rehabilitation on cervical muscle activation, cervical proprioception, and migraine burden.",[28],[58,59,60,61],"Cervical Sensorimotor Rehabilitation","Joint Position Error","Cervical Muscle Activation","EMG","NOT_YET_RECRUITING","2026-08-17",{"date":65,"type":33},"2026-08-18",{"date":67,"type":22},"2026-08-25",{"date":69,"type":22},"2027-03-01",{"name":71,"class":72},"Beni-Suef University","OTHER",{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100652101","effect-of-nebulized-dexmedetomidine-on-central-sensitization-and-chronification-in-migraine-100652101","NCT07769255","Effect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in Migraine","Effect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in Migraine: A Randomized Controlled Trial Using Calcitonin Gene Related Peptide and Trigeminal Neurophysiological Biomarkers","Inclusion Criteria:\n\n* Diagnosis of Early chronic migraine (\\\u003C6 months of ≥15 headache days\u002Fmonth), per ICHD-3 criteria.\n* No preventive migraine therapy in the prior 8 weeks.\n\nExclusion Criteria:\n\n* Presence of cardiopulmonary, psychiatric, or neurological comorbidities.\n* Current use of sedatives, opioids, or CGRP-targeting therapies.\n* Pregnancy or breastfeeding.",{"count":81,"type":22},146,[54],"Migraine is a debilitating neurological disorder characterized by recurrent headaches episodes, often accompanied by amplified perception of multiple sensory inputs such as cutaneous allodynia, photophobia, and phonophobia. The suggested mechanism in migraine is likely through sensitized trigeminovascular and dysfunctional pain modulatory systems.\n\nDexmedetomidine, a selective α2-adrenergic receptor agonist, exerts central antinociceptive effects by reducing neuronal hyperexcitability, glial activation, and CGRP expression. Nebulized administration provides a non-invasive alternative to intravenous use, with rapid CNS absorption and minimal sedation .",[28],"2026-08-12",{"date":63,"type":33},{"date":88,"type":22},"2026-09-01",{"date":90,"type":22},"2027-03-10",{"name":71,"class":72},1,{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":18,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":105,"conditions":106,"keywords":114,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100507610","responding-with-evidence-and-access-for-childhood-headaches-100507610","NCT05889624","Responding With Evidence and Access for Childhood Headaches","Cognitive Behavioral Therapy Via Telehealth + Amitriptyline Compared to Cognitive Behavioral Therapy Via Telehealth: Pediatric Migraine Prevention (Responding With Evidence and Access for Childhood Headaches)","Inclusion Criteria:\n\n* Diagnosis: Migraine with or without aura that meets the International Classification of Headache Disorders (ICHD) criteria 5 or presentation of continuous headache that includes migranous episodes based upon headache history obtained by site PI or designee. (includes presentation with or without medication overuse headache as well)\n* Headache Frequency: 4 or more headache days based upon prospective headache diary of 28 days prior to randomization\n* Amitriptyline Eligible: Site PI or medical staff determined participant to be eligible for clinical prescription of amitriptyline as a preventive treatment for migraine\n* English fluency: Able to complete the study visits and questionnaires in English\n\nExclusion Criteria:\n\n* Current treatment includes amitriptyline and\u002For CBT specific to headache care\n* Current prescribed preventive antimigraine medication within a period equivalent to \\\u003C 5 half-lives of that medication before entering the baseline phase\n* Current treatment with onabotulinumtoxinA (Botox) or CGRP-based monoclonal antibody medications for migraine prevention\n* Youth who are pregnant\n* Report of current or ongoing suicidal thoughts. Suicide attempt within the past six months. History of bipolar disorder, prolonged QT, or pre-existing significant constipation or gastroparesis\n* Any and all other diagnoses or conditions which, in the opinion of the site investigator, would prevent the patient from being a suitable candidate for the study or interfere with the medical care needs of the participant","10 Years","17 Years",{"count":103,"type":22},400,[54],"This comparative effectiveness study will clarify current first-line preventive treatment approaches for use by neurologists, psychologists, and primary care providers in the context of real world care, and will demonstrate the feasibility of Cognitive Behavioral Therapy (CBT) via telehealth for youth with migraine. The focus is on applying evidence-based care and enhancing access to it. CBT via telehealth while taking a clinically-prescribed, pill-based prevention therapy (amitriptyline) will be compared to CBT via telehealth alone.",[107,108,109,110,111,112,113,28],"Headache","Headache Disorders","Headache, Migraine","Migraine","Migraine Disorders","Migraine With Aura","Migraine Without Aura",[115,116,117,118,119,120,121,122,123],"headache","migraine","cognitive behavioral therapy","pediatrics","diaphragmatic breathing","progressive muscle relaxation","imagery","relaxation","biofeedback","2026-08-06",{"date":126,"type":33},"2026-08-10",{"date":128,"type":33},"2023-08-22",{"date":130,"type":22},"2027-12-31",{"name":132,"class":72},"Children's Hospital Medical Center, Cincinnati",15,{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100550697","the-reclaim-study-100550697","NCT06450444","The RECLAIM Study.","Randomized, Double-blind, Controlled Trial to Investigate Combined Occipital and Supra-orbital Neuromodulation in Resistant Migraine. The RECLAIM Study.","RECLAIM","Inclusion Criteria:\n\n* Diagnosis of migraine as defined by the ICHD-3 Classification (with or without aura) with a history of chronic or high-frequency episodic migraine for at least 1 year prior to screening\n* Failure of 3 or more preventive pharmacological therapies\n* Stable on preventive migraine treatments\n* Psychologically stable\n\nExclusion Criteria:\n\n* Concomitant invasive or non-invasive neuromodulation\n* Previous exposure to an implantable neuromodulation device for headache\n* Have an existing active implantable medical device nearby the implant location (e.g. DBS, cochlear implant)\n* Use of onabotulinum toxin A injections for the treatment of migraine in the past 3 months.\n* Use of local corticosteroid injections in the occipital or supra-orbital region in the past 3 months prior to enrollment.\n* Not pregnant, nursing or not using contraception","84 Years",{"count":41,"type":22},[54],"The purpose of this study is to evaluate the safety and performance, including clinical benefit, of the PRIMUS System for the treatment of Resistant Migraine.",[28,147],"High Frequency Episodic Migraine","2026-08-05",{"date":124,"type":33},{"date":151,"type":33},"2024-06-24",{"date":153,"type":22},"2029-01-31",{"name":155,"class":40},"Salvia BioElectronics",11,{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":182},"100564122","phase-2-a-study-to-evaluate-ipn10200-safety-and-efficacy-in-the-prevention-of-episodic-or-chronic-migraine-in-adults-100564122","NCT06625060","A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults","A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults","MERANTI","Inclusion Criteria:\n\n1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF. Participant has provided written informed consent and signed privacy\u002Fdata protection documentation;\n2. Male or female ≥18 to 80 years of age at the time of signing the informed consent;\n3. Diagnosis of either EM or CM, per ICHD-3 criteria, for at least 12 months prior to the screening visit;\n4. Diagnosis of migraine at ≤50 years of age;\n5. Participants in the EM group: History of EM diagnosis and headache frequency (i.e. migraine and non-migraine headache): ≤14 headache days in the 4 weeks prior to randomisation on study Day 1 based on information recorded in the eDiary; migraine frequency: ≥6 migraine days in the 4 weeks prior to randomisation on study Day 1 based on information recorded in the eDiary;\n6. Participants in the CM group: History of CM diagnosis and headache frequency (i.e. migraine and non-migraine headache): ≥15 headache days in the 4 weeks prior to randomisation on study Day 1 based on information recorded in the eDiary; migraine frequency: ≥8 migraine days in the 4 weeks prior to randomisation on study Day 1 based on information recorded in the eDiary;\n7. Participant with a history of use of at least one preventive treatment for migraine.\n\nExclusion Criteria:\n\n1. History or current diagnosis of migraine with brainstem aura, retinal migraine, complications of migraine, tension-type headache, trigeminal autonomic cephalalgias, hypnic headache, hemicrania continua or new daily persistent headache;\n2. Headache attributed to another disorder (e.g. secondary headaches), except medication overuse headache (MOH);\n3. Current uncontrolled psychiatric or psychological condition, or one that could confound assessment of headaches\u002Fmigraines or interfere with study participation;\n4. Risk of self-harm or harm to others as evidenced by past suicidal behaviour or endorsing items 3, 4, or 5 on the C-SSRS at screening or Day 1.\n5. Participants presenting with a swallowing disorder of any origin which might be exacerbated by botulinum toxin treatment, such as:\n\n   \\- Grade 3 or 4 on the Dysphagia Severity Scale (severe dysphagia) with swallowing difficulties and requiring a change in diet.\n6. Clinically relevant skin condition or infection that could interfere with injection of study intervention;\n7. Participant has any medical condition or situation that would make them unsuitable for participation in the study;\n8. Participant receiving more than one allowable concomitant migraine preventive treatment;\n9. Known history of an inadequate response to \\>4 medications prescribed for the prevention of migraine (2 of which have different mechanisms of action to botulinum toxin);\n10. Use of any of the following medications in the specified timeframe prior to the screening visit:\n\n    * Botulinum toxin for migraine within 24 weeks (or for any other medical\u002Faesthetic reason within 16 weeks);\n    * Prior use of mAbs blocking CGRP pathway within 12 weeks for preventative treatment of migraine\n    * Prior use of oral CGRP receptor antagonist (gepants) for preventative treatment of migraine within 2 weeks;\n    * Anaesthetic or steroid injection in any region targeted for treatment with study medication within 4 weeks;\n    * Use of cannabidiol or other types of cannabinoids within 30 days;\n    * Use of medical device to treat migraine within 4 weeks (e.g. non-invasive neuromodulation therapies such as nerve stimulation (gammaCore), transcranial magnetic stimulation (cephaly), external trigeminal nerve stimulation, transcutaneous electrical nerve stimulation and peripheral neuroelectrical stimulation);\n    * Use of other intervention to treat migraine that is assessed to interfere with study evaluations within 4 weeks (e.g. acupuncture in the head and neck region, cranial traction, nociceptive trigeminal inhibition, occipital nerve block treatments and dental splints for headache);\n    * Use of opioids or barbiturates for more than 2 days\u002Fmonth within the last 4 weeks.\n11. Concurrent participation in another interventional clinical study (or within specified timeframe according to national or local legislation or requirements);\n12. Diagnosis of other significant pain disorders that could confound the assessment of headaches\u002Fmigraines or interfere with study participation, including but not limited to chronic pain disorders such as fibromyalgia, chronic low back pain and complex regional pain syndrome;\n13. Pregnant women, nursing women, premenopausal women, or WOCBP (i.e. not surgically sterile or 1 year postmenopausal) not willing to practice an acceptable contraceptive method, at the beginning of the study and for a minimum of 12 weeks following the administration of study treatment;\n14. Male subjects who are not vasectomised and who have female partners of childbearing potential and are not willing to use condoms with spermicide for a minimum of 12 weeks following the initial double-blind administration of the treatment;\n15. History of alcohol or drug abuse within 5 years of the screening visit (excluding medication overuse for headache);\n16. Body mass index (BMI) ≥35 kg\u002Fm² at the screening visit;\n17. Known clinically significant hypersensitivity to any of the study drugs, excipients or materials used to administer the study drug;\n18. Patients who, in the clinician's judgment, are actively suicidal, and therefore, deemed to be at significant risk for suicide.\n19. A diagnosis of a neuromuscular disorder or respiratory disorder, such as myasthenia gravis, Lambert-Eaton syndrome or amyotrophic lateral sclerosis that in the opinion of the investigator would compromise the safety of the study participant.","80 Years",{"count":167,"type":22},641,[169],"PHASE2","A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. Corabotase (also known as IPN10200) is a medication that stops the release of these chemical messengers.\n\nParticipants with episodic migraine (EM) or chronic migraine (CM) will be included in both Step 1 and Step 2. \"Headache days\" are when participants experience headaches that meet the criteria for a migraine or a headache without the additional migraine-specific symptoms. \"Migraine days\" occur when the headache displays clear migraine characteristics.\n\nThis study aims to determine:\n\n* The safety and efficacy of injecting Corabotase directly into the muscles of the head and neck to prevent EM and CM,\n* The right amount (dose) of Corabotase to inject at each point,\n* The total amount (dose) of Corabotase that provides the best balance between safety and efficacy preventing migraines.\n\nParticipants will need to complete a daily electronic migraine Diary (eDiary) and questionnaires throughout the study. The total study duration for a participant will be up to 44 weeks.",[172,28],"Episodic Migraine","2026-07-27",{"date":175,"type":33},"2026-07-28",{"date":177,"type":33},"2024-10-10",{"date":179,"type":22},"2027-10-31",{"name":181,"class":40},"Ipsen",166,{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":23,"phases":193,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":92},"100485257","phase-3-botox-vs-xeomin-for-chronic-migraine-100485257","NCT05598723","BOTOX® vs. XEOMIN® for Chronic Migraine","A Randomized, Double-Blind Study on the Effect of OnabotulinumtoxinA (BOTOX®) vs. IncobotulinumtoxinA (XEOMIN®) Botulinum Toxin in Adults With Chronic Migraine","Inclusion Criteria:\n\n* Between ages of 18-89\n* 15 or more headaches days experienced per month lasting 4 hours or longer\n* Department of Defense (DoD) Beneficiary\u002FTriCare Eligible\n* Failure, contraindication or intolerance to two migraine medications from two different classes.\n* Able to provide informed consent and be able to read and write English.\n* Able to read, comprehend, and complete the assessment and diary\n* Women must provide a negative urine pregnancy test\n\nExclusion Criteria:\n\n* Currently pregnant, breastfeeding, or planning to become pregnant\n* Allergic to botulinum toxin or to any of the ingredients of the medication\n* Has myasthenia gravis, amyotrophic lateral sclerosis, or Eaton Lambert syndrome, mitochondrial disease, fibromyalgia, any temporomandibular disfunction, or any other significant disease that might interfere with neuromuscular function.\n* Uncontrolled epilepsy defined as more than 1 generalized seizure in any month within the 3 months prior to the day 0 visit\n* Those on oral anticoagulation\n* Previous botulinum toxin treatment on the cephalic\u002Fupper lumbar region within 6 months for any indication\n* Localized infections on face, neck or on antibiotics for areas in this region\n* Unable to attend study follow up visits for any reason (i.e. Training, deployment, or PCS)\n* Use of any prophylactic headache medication between -4 weeks and week 0 visits\n* Any person taking chronic pain medication for a chronic indication\n* Any diagnosed psychiatric condition which would prohibit a participant from completing the trial in its totality.","89 Years",{"count":192,"type":22},128,[25],"Chronic migraine (CM) is a disabling disorder that sidelines active duty personnel and diminishes their quality of life. It affects 1.3% to 2.4% of the general population. These numbers increase in active duty personnel, especially those returning from deployment, as well as in veterans. Furthermore, these numbers are 4-5 times higher in military members who experienced at least one mild traumatic brain injury. CM leads to impaired cognition and poor decision-making. These impairments on critical active duty tasks could have a significant impact on task readiness and military performance. Therefore, CM presents a challenge for the \"return to duty\" mission. Currently, onabotulinumtoxinA is the only FDA-approved prophylactic treatment for CM; however, this treatment requires refrigeration, to which there is little access for the forward-deployed members who have limited access to adequate storage for this treatment. Therefore, it is imperative to identify a CM treatment that does not require refrigeration. Furthermore, in light of the ongoing COVID-19 pandemic and resulting international shortages in critical medication production and delivery, it is imperative to identify more than one treatment option for the management of CM. In this study, we will test the efficacy of incobotulinumtoxinA, a neurotoxin that, unlike onabotulinumtoxinA, does not require refrigeration, but is an effective off-label alternative for the treatment of migraine. OnabotulinumtoxinA and incobotulinumtoxinA are comparable in strength, with a conversion ratio of 1:1.",[28],[197,198,199,200,201,202,203],"Botox","Xeomin","onabotulinumtoxinA","incobotulinumtoxinA","Botulinum Toxin","refrigeration","HIT-6","2026-07-21",{"date":206,"type":33},"2026-07-22",{"date":208,"type":33},"2023-02-24",{"date":210,"type":22},"2027-08-24",{"name":212,"class":213},"Naval Medical Center Camp Lejeune","FED",{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":18,"minAge":222,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":225,"phases":4,"briefSummary":226,"conditions":227,"keywords":228,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":240},"100562468","post-marketing-study-to-assess-the-safety-and-effectiveness-of-oral-atogepant-in-korean-adult-participants-for-the-prevention-of-chronic-or-episodic-migraine-100562468","NCT06603558","Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine","Post-marketing Surveillance Study to Evaluate the Safety and Effectiveness of Atogepant for the Prevention of Migraine in Korean Adult Patients","Atogepant PMSS","Inclusion Criteria:\n\n* Participants with migraine suitable for the treatment with atogepant according to the latest approved local label.\n* Participants prescribed atogepant in accordance with the approved local label.\n\nExclusion Criteria:\n\n* Participants with any contraindication to atogepant as listed on the latest approved local label.\n* Participants currently participating in another clinical research except observational study.","19 Years",{"count":224,"type":22},3000,"OBSERVATIONAL","Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and\u002For sensitivity to light and sound. The study will assess the safety and effectiveness of atogepant for the preventive treatment of migraine in Korean adult patients with chronic migraine or episodic migraine under routine clinical practice.\n\nAtogepant is an approved drug for preventive treatment of migraine in adults. Approximately 3000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study in Korea.\n\nParticipants will receive atogepant oral tablets as prescribed by their physician. Participants will be followed for up to week 12.\n\nThere is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.",[28,172,110],[28,172,110,229,230,231],"Atogepant","Qulipta","Aquipta","2026-07-20",{"date":206,"type":33},{"date":235,"type":33},"2024-09-24",{"date":237,"type":22},"2029-05",{"name":239,"class":40},"AbbVie",36,{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":49,"sex":18,"minAge":19,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":251,"briefSummary":252,"conditions":253,"keywords":254,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":265},"100553380","phase-2-prophylactic-treatment-with-atorvastatin-for-chronic-migraine-chronicstatinmig-100553380","NCT06485336","Prophylactic Treatment With Atorvastatin for Chronic Migraine (ChronicStatinMig)","ChronicStatinMig. A Multicentre, Triple Blind, Placebo Controlled, Parallel Group Study of Atorvastatin in Chronic Migraine","Inclusion Criteria:\n\n1. Age 18 to 64 years\n2. Signed informed consent\n3. Chronic migraine according to ICHD-3 criteria (32)\n4. At inclusion, patients should retrospectively have at least 15 headache days per month wheof at least 8 migraine days during the last 3 months. This frequency must be confirmed in the headache diary before randomisation to treatment (See below).\n5. Debut of migraine at least one year prior to inclusion based on information in the patient record or by careful examination of previous headache history\n6. Start of migraine before age 50 years.\n7. No use of other migraine prophylactics during the study\n8. For women of child-bearing potential (WOCBP, see below) there must be no pregnancy or planned pregnancy during the study period, and use of highly effective contraception (See below).\n\nAfter the baseline period, just before randomisation to the study drug, inclusion criteria will be evaluated once more, and the headache diary will be evaluated. If there are, according to the headache diary, fewer migraine days than 8 per month, the baseline period can be extended to 8 weeks.\n\nExclusion Criteria:\n\n1. Medication overuse headache requiring detoxification from acute medication (triptans, opioids). Exception could be made for those fulfilling A and B:\n\n   A. Have tried a withdrawal period of at least 2 months without impact on headache frequency B: Use of opioids (of any type) ≤ 8 days \u002Fmonths.\n2. Pregnancy, planning to get pregnant, inability to use contraceptives (See inclusion criteria, point 8), and lactating\n3. Clinical information on or signs of cholestasis or decreased hepatic or renal function.\n4. High degree of comorbidity and\u002For frailty associated with reduced life expectancy or high likelihood of hospitalization, at the discretion of the investigator\n5. Hypersensitivity to statins or previous use of statins\n6. History of angioneurotic oedema\n7. Use of medicines for migraine prophylaxis less than 4 weeks, or of botulinum toxin less than 16 weeks, prior to start of study\n8. Current use of antiviral treatment agaist hepatitis C\n9. Significant psychiatric illness\n10. Alcohol or illicit drug dependence.\n11. Inability to understand study procedures and to comply with them for the entire length of the study\n12. Treatment for hypothyroidism\n13. Lactose intolerance","65 Years",{"count":250,"type":22},300,[169],"The main objective of this study is to see whether the favorable preventative effect of Atorvastatin 40mg per day in episodic migraine, that was found previously in three smaller randomized controlled cross-over studies, can be confirmed in a larger, multicenter, randomized controlled parallel group study. In addition it will be investigated whether 1) the favorable side effect profile, seen in previous studies, can be confirmed, and whether it is even better with the smaller dose, and 2) estimating the cost of Atorvastatin treatment, considering cost of medicine, cost of acute attack medicine, and cost of lost worktime.",[28],[110,255,256],"Atorvastatin","Randomized controlled trial","2026-07-16",{"date":232,"type":33},{"date":260,"type":33},"2024-05-01",{"date":262,"type":22},"2029-02-28",{"name":264,"class":72},"St. Olavs Hospital",6,{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":18,"minAge":273,"maxAge":101,"enrollmentInfo":274,"targetDuration":4,"studyType":23,"phases":276,"briefSummary":277,"conditions":278,"keywords":279,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":290},"100578377","phase-3-a-study-of-oral-atogepant-tablets-to-assess-adverse-events-and-change-in-disease-activity-to-prevent-migraine-in-participants-aged-12-to-17-years-100578377","NCT06810505","A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years","A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age","Inclusion Criteria:\n\n* History of chronic migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3) (2018) for at least 6 months as of Visit 1.\n* During the last 28 days of the screening\u002Fbaseline period, and as per eDiary:\n\n  * Participant must have completed the eDiary for a minimum of 20 out of 28 days.\n  * Participant has \\>= 15 headache days.\n  * Participant has \\>= 8 migraine days.\n\nExclusion Criteria:\n\n* Clinically significant hypertension per investigator's judgment.\n* History of any clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, cardiovascular or neurologic disease.","12 Years",{"count":275,"type":22},420,[25],"Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. The goals of the study are to evaluate adverse events and how well treatment of atogepant works compared to placebo (looks like the study treatment but contains no medicine) in preventing chronic migraine in participants between 12 and 17 years of age.\n\nAtogepant is a medicine currently approved in the United States and Europe for the preventive treatment of migraine in adult patients with migraine and is being studied for the preventative treatment of chronic migraine in participants between the ages of 12 and 17 years. Participants will be randomly assigned to one of the 2 groups to be treated with either atogepant or placebo. This study is double-blinded, which means that neither the patients nor the study doctors know who is given which study treatment. Approximately 420 participants 12 to 17 years of age with chronic migraine will be enrolled at approximately 70 sites across the world.\n\nParticipants will receive oral tablets of atogepant or placebo once daily for 12 weeks and will be followed for 4 weeks.\n\nParticipants will attend regular visits during the study at a hospital or clinic and the effects of treatment will be checked by completion of a daily diary, medical assessments, blood tests, checking for side effects, and completing questionnaires.",[28],[110,28,229,280,281],"QULIPTA","AQUIPTA","2026-07-13",{"date":284,"type":33},"2026-07-14",{"date":286,"type":33},"2025-02-13",{"date":288,"type":22},"2031-03",{"name":239,"class":40},64,{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":23,"phases":300,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":92},"100646489","evolution-of-the-cognitive-profile-and-quality-of-life-of-adult-patients-suffering-from-severe-migraines-under-preventive-treatment-100646489","NCT07691164","Evolution of the Cognitive Profile and Quality of Life of Adult Patients Suffering From Severe Migraines Under Preventive Treatment","CEREB","Inclusion Criteria:\n\nAdult patient (legal age) Adult patient suffering from severe treatment-resistant migraine, according to the ICHD-3 criteria, i.e. more than 8 migraine days per month (high-frequency episodic migraine and chronic migraine) Headache condition indicating treatment with botulinum toxin type A according to the PREEMPT protocol or infusion of anti-CGRP antibodies (Eptinezumab) Subject affiliated with a social health insurance scheme Subject able to understand the objectives and risks related to the research and able to provide informed, dated, and signed consent\n\nExclusion Criteria:\n\nPatient suffering from a central neurological disorder or sequelae (multiple sclerosis, traumatic brain injury with loss of consciousness, stroke, dementia, etc.) Patient suffering from another chronic pain condition (fibromyalgia, low back pain, etc.) Patient suffering from a psychiatric disorder other than anxiety-depressive syndrome Patient suffering from severe disabling auditory or visual impairment, such as profound hearing loss not correctable with hearing aids or blindness\n\nContraindication to the treatment prescribed as part of routine care:\n\nBotulinum toxin type A: pregnancy, allergic hypersensitivity, myasthenia gravis, Lambert-Eaton syndrome, infection at the injection site Eptinezumab: pregnancy, allergic hypersensitivity, severe cardiovascular disease (stroke, transient ischemic attack, myocardial infarction, coronary artery bypass surgery) Patient currently in an exclusion period (determined by a previous or ongoing study) Inability to provide the subject with informed information (emergency situation, comprehension difficulties, etc.) Subject under judicial protection Subject under guardianship or curatorship Pregnant or breastfeeding woman\n\n\\-",{"count":299,"type":22},60,[54],"In chronic migraine, we routinely use innovative treatments such as peri-cranial injections of botulinum toxin type A according to the PREEMPT protocol, or intravenous Eptinezumab, both targeting the Calcitonin Gene-Related Peptide (CGRP). We observe significant improvement in 70-80% of our patients after one year of treatment, corresponding to at least a 30-50% reduction in the number of migraines per month, together with improvements in anxiety and depression comorbidities (HADS), catastrophizing scores (PCS), and the impact of migraines on quality of life (HIT-6).\n\nOur main hypothesis, based on our clinical experience and the literature, is that the cognitive profile of these adult patients-particularly attention and memory, as assessed by a validated self-report questionnaire-improves following treatment with botulinum toxin type A administered according to the PREEMPT protocol or intravenous anti-CGRP antibody infusions (Eptinezumab), alongside improvement in migraine disease activity (number of migraines per month), after one year of treatment.",[28],"2026-07-06",{"date":305,"type":33},"2026-07-08",{"date":307,"type":22},"2026-10-01",{"date":309,"type":22},"2029-09-30",{"name":311,"class":72},"University Hospital, Strasbourg, France",{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":49,"sex":319,"minAge":19,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":23,"phases":323,"briefSummary":324,"conditions":325,"keywords":326,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":92},"100598101","suppressive-functions-of-regulatory-t-cells-in-migraine-100598101","NCT07067112","Suppressive Functions of Regulatory T Cells in Migraine","SIIM-reg","Inclusion Criteria:\n\n* Females\n* 18 to 50 years old\n* Chronic migraine participants : chronic migraine (at least 15 days of headache\u002Fmonth, according to the International Classification of Headache Disorders, 3rd edition criteria\n\nExclusion Criteria:\n\n* BMI \\\u003C or = 17kg\u002Fm² or \\> or = 30kg\u002Fm²\n* Diagnosis or suspicion of type 2 diabetes, auto-immune or inflammatory diseases, immunodeficiency diseases\n* Diagnosis of headache of non-migraine origin, except for tension type headache \\\u003C or = 4 days per month (i.e.: cluster headache, post-traumatic headache, cerebral tumour…)\n* Pregnancy, delivery, miscarriage, breastfeeding, participation in a medically assisted human reproduction program (ovary stimulation\u002Fhormone therapy) \\\u003C 3 months before blood sampling\n* Menopause, hysterectomy, or bilateral oophorectomy\n* Flare of the autoimmune\u002Finflammatory disease of interest \\\u003C 1 month before blood sampling\n* Modification of maintenance therapy for the autoimmune\u002Finflammatory disease of interest (start, change of molecule, interruption) \\\u003C 3 months before blood sampling\n* Modification of prophylactic anti-migraine therapy (start, change of molecule, interruption) \\\u003C 3 months before blood sampling (for migraine participants)\n* Hormone therapy (besides contraception and treatment of endometriosis)\n* Transplantation (solid organ or bone marrow)\n* Cancer (active or remitting) \\\u003C 1 year before blood sampling (solid organ or blood)\n* Haematologic disease (benign or malignant) of the lymphoid lineage\n* Guardianship, curatorship, safeguard of justice or deprivation of liberty\n* For controls : diagnosis of migraine","FEMALE","50 Years",{"count":322,"type":22},24,[54],"Migraine is a frequent, disabling condition, of great social and economical impact worldwide. This condition is more frequent in women and subjects with autoimmune and\u002For inflammatory diseases. Cytokine and immune cell dysregulations have been evidenced in migraine. Inflammation seems to play an important role in migraine chronification; however, the inflammatory mechanisms involved in migraine pathophysiology remain unclear. Regulatory T (Treg) cells play a central role in maintaining immune homeostasis. They regulate effector T (Teff) cell proliferation and cytokine production, through several suppressive mechanisms, such as the hydrolysis of adenosine triphosphate (ATP) into adenosine (ADO), mediated by surface enzymes Cluster Differentiation 39 (CD39) and Cluster Differentiation 73 (CD73). ATP is involved in pain processes in migraine, and insufficient hydrolysis could participate in pain chronification. Recent studies suggest altered proportions of Treg cells in migraine, and decreased levels of CD39-positive (CD39+) Treg cells, suggesting Treg suppressive functions may be decreased in the disease. However, there have been no functional studies to date to confirm this hypothesis.\n\nThe investigators believe Treg suppressive functions may be decreased in migraine, and that such alterations may be caused by a malfunction in the ADO pathway.",[28],[110,327,328,329],"Inflammation","Immune system","Regulatory T cells","2026-06-18",{"date":332,"type":33},"2026-06-22",{"date":334,"type":22},"2026-07-01",{"date":336,"type":22},"2027-11-30",{"name":338,"class":72},"University Hospital, Clermont-Ferrand",{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":18,"minAge":100,"maxAge":101,"enrollmentInfo":345,"targetDuration":4,"studyType":23,"phases":347,"briefSummary":348,"conditions":349,"keywords":350,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":360},"100417438","mind-body-balance-for-pediatric-migraine-100417438","NCT04715685","Mind Body Balance for Pediatric Migraine","Inclusion Criteria:\n\n* Diagnosis: Migraine with or without aura or chronic migraine that meets the International Classification of Headache Disorders(ICHD) criteria\n* Frequency: Headache frequency based upon prospective headache diary of 28 days must be ≥ 4 and ≤ 28.\n* PedMIDAS: PedMIDAS Disability Score \\> 4, indicating at least mild disruption in daily activities and \\\u003C 140, indicating extreme disability that may require more comprehensive, multi-component therapy\n* Use of one or more of the following prescribed nutraceuticals and\u002For preventive anti-migraine medications at the time or randomization or be on a stable dose of one or more of the following throughout the 12 weeks of the study \\[Vitamin B2 (Riboflavin), Co-Q 10 (Coenzyme Q10), Magnesium (Mg), Vitamin D2 or D3 (Erocalciferol\u002FCholecalciferol), Depakote (Divalproate), Inderal (Propanerol), Elavil ((Amitripyline), Topamax (Topiramate), Periactin (Cyproheptadine)\\]\n* Language: English speaking, able to complete interviews and questionnaires in English\n\nExclusion Criteria:\n\n* Continuous migraine defined as unrelenting headache for a 28 day period\n* Must agree not to take non-specific acute medication, such as NSAIDS (e.g., ibuprofen), more than 3 times per week, or migraine specific acute medications, such as triptans, more than 6 times per month (to prevent medication overuse headache)\n* PedMIDAS Disability Score \\> 140, indicating extreme disability that may require more comprehensive, multi-component therapy\n* Youth who are pregnant, or those who are sexually active and not using a medically accepted form of contraception (barrier or hormonal methods)\n* Present severe psychiatric disease, alcohol or drug dependence, or documented developmental delays or impairments (e.g., autism, cerebral palsy, or mental retardation) or other circumstances, that, in the opinion of the investigator, would interfere with adherence to study requirements or safe participation in the study",{"count":346,"type":22},260,[54],"This study uses a factorial research design to evaluate a nurse delivered mind body intervention using different doses of 3 treatment components to determine the optimized treatment for headache day reduction.",[107,108,109,110,111,112,113,28],[115,116,117,118,351,119,120,121,122,123],"mind body intervention","2026-06-14",{"date":354,"type":33},"2026-06-16",{"date":356,"type":33},"2021-03-09",{"date":358,"type":22},"2026-11-30",{"name":132,"class":72},2,{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":23,"phases":370,"briefSummary":371,"conditions":372,"keywords":373,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":92},"100529169","sequential-multiple-assignment-double-randomized-preference-migraine-behavioral-trial-100529169","NCT06170281","Sequential, Multiple Assignment, Double Randomized Preference, Migraine Behavioral Trial","A Feasibility Clinical Trial Assessing Patient Preference, Optimum Combinations and Sequences of a Multicomponent, Virtually-Delivered Migraine Behavioral Intervention","SMARTMig","Inclusion Criteria:\n\n* have chronic migraine for a minimum of 1-year\n* aged 18 years and older\n\nExclusion Criteria:\n\n* secondary headache disorders\n* children younger than 18 years old",{"count":322,"type":22},[54],"This study will unpack the behavioral intervention for migraine and determine the optimum combinations. In addition, the study will test preference and self-selection effects during the trial.",[110,107,28,108],[116,115,374],"behavioral intervention","2026-06-12",{"date":354,"type":33},{"date":378,"type":22},"2026-12",{"date":380,"type":22},"2028-12-01",{"name":382,"class":72},"Mayo Clinic",{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":391,"targetDuration":393,"studyType":225,"phases":4,"briefSummary":394,"conditions":395,"keywords":397,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":360},"100600915","i-need-new-migraine-drugs-database-100600915","NCT07103694","i-NEED: NEw migrainE Drugs Database","Italian Real-life Multicenter Observational Study on Efficacy, Tolerability, and Safety of Innovative Drugs (Monoclonal Antibodies, Gepants, Ditans, Sumatriptan-naproxen) for Preventive or Acute Migraine Treatment.","i-NEED","Inclusion Criteria:\n\n* Age more or equal 18 years;\n* Males and females;\n* Willingness to sign the informed consent;\n* Episodic migraine for the use of drug indicated for migraine attack\n* High frequency episodic migraine, at least 8 days per month of disabling migraine in the past 3 months;\n* Chronic migraine, according to the ICHD-III criteria;\n\nExclusion Criteria:\n\n* Other headaches different than migraine;\n* Known intolerance to the eccipients;\n* Vascular disease or Raynaud.",{"count":392,"type":22},2641,"3 Years","Approved by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) starting in 2018, anti-CGRP monoclonal antibodies (anti-CGRP mAbs) represent the first true revolution in the preventive treatment of migraine due to their selectivity and specificity. To date, four anti-CGRP mAbs have been developed for the preventive treatment of migraine: eptinezumab, erenumab, fremanezumab, and galcanezumab.Anti-CGRP mAbs constitute not only the first specific and selective treatment for the prevention of migraine but also the most extensively studied pharmacological category in this field, considering the vast and complex populations examined. The clinical effects of the various mAbs are substantially comparable and are characterized by several fundamental aspects:\n\n* High efficacy in both episodic and chronic migraine, with the presence of super-responders who experience a reduction in the average monthly number of migraine days of \\>75% (or even 100%) compared to before treatment.\n* Efficacy that is independent of the clinical form of migraine - with or without aura - and regardless of whether there is analgesic overuse.\n* Efficacy maintained even in the presence of depressive or anxious comorbidities.\n* Rapid onset of action (even more pronounced with eptinezumab), with the therapeutic effect appearing within the first week in most cases.\n* Excellent tolerability with an absence of class-specific adverse events.\n* Outstanding treatment adherence and a very low rate of treatment discontinuation in the long term. It should also be noted that the development of anti-drug antibodies or neutralizing antibodies to anti-CGRP mAbs is rare and does not significantly impact the efficacy or tolerability of treatment. Future clinical practice will need to clarify several additional aspects, such as: 1) whether treatment with anti-CGRP mAbs can modify the course of migraine; 2) the appropriate approach regarding any traditional preventive treatment (whether to continue or discontinue it); 3) the definition of the characteristics of non-responders; 4) the definition of patients with a delayed response to treatment.\n\nGepants are oral antagonists of the CGRP receptor. Among the four gepants synthesized so far (atogepant, rimegepant, ubrogepant, zavegepant), atogepant and rimegepant are currently available in Italy. Atogepant has proven to be an effective and well-tolerated option for the prevention of episodic and chronic migraines. Rimegepant is effective for both acute treatment and prevention of migraines, with a favorable safety profile and flexible oral administration. Lasmiditan is the first ditan effective for migraine attack and it represents a new therapeutic option for patients with contraindications to triptans, due to the presence of vascular risk factors, or for patients who experience undesirable side effects with these, thus increasing the therapeutic possibilities for the symptomatic treatment of migraine. The combination of sumatriptan 85 mg and naproxen sodium 500 mg is indicated for the acute treatment of migraine attacks in adult patients for whom sumatriptan monotherapy is insufficient.",[172,28,396],"Medication Overuse Headache",[398],"migraine, anti-CGRP monoclonal antobodies, gepants, ditans, sumatriptan and naproxen combination","2026-06-09",{"date":401,"type":33},"2026-06-11",{"date":403,"type":33},"2022-03-24",{"date":405,"type":22},"2026-12-31",{"name":407,"class":72},"IRCCS San Raffaele Roma",{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":248,"enrollmentInfo":415,"targetDuration":4,"studyType":23,"phases":417,"briefSummary":418,"conditions":419,"keywords":421,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":435},"100643394","fire-needling-plus-filiform-needling-for-chronic-migraine-with-comorbid-tension-type-headache-100643394","NCT07633522","Fire Needling Plus Filiform Needling for Chronic Migraine With Comorbid Tension-Type Headache","Clinical Research on Fire Needling Combined With Filiform Needling for Chronic Migraine With Comorbid Tension-type Headache","Inclusion Criteria:\n\n* Meets the diagnostic criteria for tension-type headaches with pericranial tenderness;\n* Meets the diagnostic criteria for chronic migraine;\n* 18 years ≤ age ≤ 65 years;\n* Has sufficient understanding to complete the necessary examinations and tests for the study;\n* Voluntarily joins this study and signs the informed consent form.\n\nExclusion Criteria:\n\n* Patients complicated with cluster headache or other primary headaches;\n* Patients with secondary headaches caused by intracranial space-occupying lesions, cranial infections, etc.;\n* Patients complicated with severe heart, liver or kidney impairment, coagulation disorders, infections, severe immunocompromise, or allergic predisposition;\n* Patients with alcohol or drug dependence;\n* Patients who are unable to cooperate with acupuncture treatment;\n* Women who are planning pregnancy, pregnant or breastfeeding;\n* Patients who have received acupuncture treatment within 3 months prior to enrollment.",{"count":416,"type":22},88,[54],"The investigators conducted a multicenter, prospective, randomized controlled clinical study to learn whether fire needling combined with filiform needling applied to pericranial muscle tenderness areas can effectively treat chronic migraine with comorbid tension-type headache. The study will also evaluate the safety and long-term efficacy of this therapy. Its main target questions include:\n\n1. Can fire needling significantly reduce the number of headache days per month?\n2. What is the effect of this therapy on headache intensity, emotional symptoms, and quality of life? The investigators will compare \"fire needling at pericranial tender points plus conventional filiform needling\" versus \"conventional filiform needling alone\" to verify whether the key technique of fire needling plus conventional filiform needling provides unique additive value.\n\nParticipants will:\n\n1. Receive treatment twice per week for 8 weeks (either in the experimental group or the control group)，attend a follow-up visit at week 24 after enrollment\n2. Keep a headache diary (recording headache frequency, pain intensity, duration, associated symptoms, etc.)\n3. Regularly complete assessments of emotional status, quality of life, and number of pericranial tender points",[28,420],"Tension-type Headache",[422,423,424,425],"fire needling","filiform needling","chronic migranie","tension-type headache","2026-06-04",{"date":428,"type":33},"2026-06-08",{"date":430,"type":22},"2026-08",{"date":432,"type":22},"2028-12",{"name":434,"class":72},"Beijing Hospital of Traditional Chinese Medicine",3,{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":23,"phases":445,"briefSummary":446,"conditions":447,"keywords":449,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":451,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":92},"100471142","determining-the-utility-of-a-behavioral-intervention-in-chronic-migraine-100471142","NCT05415020","Determining the Utility of a Behavioral Intervention in Chronic Migraine","Feasibility, Acceptability, and Pilot Testing of a Behavioral Intervention for Chronic Migraine","RLB","Inclusion Criteria:\n\n* have chronic migraine for a minimum of 1-year\n* aged 18 years and older\n\nExclusion Criteria:\n\n* other headache disorders including secondary headache disorders\n* children younger than 18 years old\n* current pregnancy",{"count":299,"type":22},[54],"This proposal will involve a pilot study to evaluate the feasibility, acceptability, and outcomes of a lifestyle behavior protocol in managing chronic migraine. Additionally, the proposal will investigate biomolecules that are uniquely involved in chronic migraine patients who respond to the protocol. Successful completion of this proposal will inform the design of a future full-scale behavioral clinical trial to control chronic migraine.",[110,107,111,28,448,108],"Lifestyle Factors",[111,107,450],"Lifestyle",{"date":428,"type":33},{"date":453,"type":33},"2022-06-29",{"date":455,"type":22},"2027-07-31",{"name":382,"class":72},{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":248,"enrollmentInfo":464,"targetDuration":4,"studyType":23,"phases":466,"briefSummary":467,"conditions":468,"keywords":469,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":360},"100316803","study-on-30-outpatients-with-chronic-migraine-treated-with-well-being-therapy-or-with-a-control-therapy-100316803","NCT03404336","Study on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Control Therapy","Pilot Randomized Controlled Trial to Evaluate the Efficacy of Well-Being Therapy vs a Control Condition in Chronic Migraine Patients","Inclusion criteria:\n\n1. able and interested in participating to the present research project, as proved by signed Informed consent;\n2. 18-65 years of age;\n3. Italian mother tongue;\n4. diagnosis of chronic migraine according to the International Classification of Headache Disorders. Thus, presenting specific features (i.e., unilateral and pulsating pain of moderate or severe intensity, which is aggravated or precipitated by routine physical activities and is combined with nausea and\u002For vomiting, photophobia, and phonophobia) and migraine headache on ≥ 15 days per month;\n5. headache chronicity for a minimum of 1 year and pattern of headache symptoms stable for a period of at least 6 months;\n6. no pharmacological therapy or dietary supplements use for chronic migraine OR pharmacological therapy\u002Fdietary supplement use for chronic migraine stable since at least 3 months;\n7. psychotropic medication allowed only if stable since at least three months.\n\nExclusion criteria:\n\n1. diagnosis of medication overuse headache;\n2. co-occurrence of psychiatric disorder(s) according to the Diagnostic and Statistical Manual of mental disorders (DSM) 5th edition as diagnosed via the MINI International Neuropsychiatric Interview;\n3. co-occurrence of chronic unstable medical conditions;\n4. being pregnant or lactating;\n5. under exogeneous hormones treatment (i.e., hormonal contraceptives, postmenopausal hormone therapy);\n6. any other condition that, according to the Investigators' opinion, may alter the ability of the patient to follow study procedures.",{"count":465,"type":22},30,[54],"Chronic migraine is a disabling type of migraine and is often resistant to treatment. Non-pharmacological interventions have been investigated as potential treatment although, unfortunately, the literature on their efficacy is poor and showed mixed results. Well-Being Therapy (WBT) is a brief psychotherapy which has shown efficacy in decreasing the relapse rates of depression in adults, in generalized anxiety disorder and in cyclothymia. It can be implemented to empower psychological well-being. The aim of the present study is to test the efficacy of WBT in a sample of patients with chronic migraine to verify if it reduces the disability due to migraine and distress, it increases the psychological well-being as well as the level of euthymia.",[28],[116,470,471,472,473],"chronic","well-being therapy","psychotherapy","therapy","2026-04-29",{"date":476,"type":33},"2026-05-05",{"date":478,"type":33},"2018-10-01",{"date":480,"type":22},"2026-12-30",{"name":482,"class":72},"University of Florence",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":18,"minAge":490,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":23,"phases":493,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":502,"locationsCount":92},"100360362","phase-2-cannabis-for-the-prophylactic-treatment-of-migraine-100360362","NCT03972124","Cannabis for the Prophylactic Treatment of Migraine","Cannabis for the Prophylactic Treatment of Migraine: a Randomized Double-Blind Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n* Subject is willing and able to give signed informed consent.\n* Male and female patients aged 25 years or older.\n* History of migraine for at least 12 months as diagnosed by the International Classification of Headache Disorders (ICHD-3).\n* Chronic migraine for at least the previous 3 months prior to screening, as diagnosed by ICHD-3.\n* Migraine preventative medications (including Botulinum toxin injections) are permitted if dose is stable for the 3 month period prior to randomization, and no change to dose is planned for the entire duration of the study.\n* Using a reliable method of contraception for females of child-bearing age.\n* Failure of at least 2 prior migraine preventatives, either due to lack of efficacy with an appropriate trial of the medication, or due to lack of tolerability.\n* Able to follow study procedures, fill out headache diaries, and complete questionnaires.\n* Completion of at least 90% of the headache diary during the one month baseline period.\n\nExclusion Criteria:\n\n* Other active primary headaches, such as cluster headache, hemicrania continua, etc.\n* Any secondary headache, such as headache related to intracranial hypertension, intracranial hypotension, hydrocephalus, intracranial mass lesion, etc.\n* Pregnant, planning to become pregnant, or breastfeeding.\n* Active or significant history of major mental illness, including severe depression, or anxiety, and any history of psychosis or schizophrenia.\n* History of or current substance use disorder.\n* Regular use of cannabis for medical or recreational reasons during the previous 12 months.\n* History of significant cardiovascular or cerebrovascular disease, such as previous myocardial infarction, stroke, or peripheral vascular disease.\n* History of hypertension greater than 160\u002F100 and not medically treated.\n* Any past history of seizure disorder.\n* Liver disease or liver enzymes two or more times the upper limit of normal at baseline.\n* Severe renal disease or GFR more than 30% below expected.\n* Any disorder or condition leading to hypersomnolence or excessive daytime drowsiness, such as narcolepsy, excessive use of sedatives\u002Fhypnotics, etc.\n* Any other medical condition that in the opinion of the investigators may pose a health risk to the subject if entered into the clinical trial.\n* Use of interventions or devices, such as nerve blocks, sphenopalatine ganglion blocks, vagal nerve stimulators, and transcranial magnetic stimulators during the baseline period (weeks -4 to 0). These treatments will also be prohibited during the period of therapy (weeks 0 to 12).\n* Use of transitional therapies such as a course of steroids or a dihydroergotamine protocol during the baseline period (weeks -4 to 0). These treatments will also be prohibited during the period of therapy (weeks 0 to 12).\n* Overuse of triptan, dihydroergotamine, opioid, or barbiturate medications, defined as 10 or more days per month in the 3 months prior to randomization.\n* Overuse of simple analgesics (such as acetaminophen, ibuprofen, aspirin), and non-steroidal anti-inflammatories (such as naproxen, ketorolac, diclofenac, etc.) defined as 15 or more days per month in the 3 months prior to randomization.","25 Years",{"count":492,"type":22},72,[169],"This study will evaluate the efficacy and safety of cannabis for the treatment of chronic migraine headaches. Study subjects will be randomized to one of three groups: lower dose CBD, higher dose CBD or placebo.",[28],"2026-04-26",{"date":498,"type":33},"2026-05-01",{"date":500,"type":33},"2026-04-01",{"date":432,"type":22},{"name":503,"class":72},"University of Calgary",{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":248,"enrollmentInfo":510,"targetDuration":4,"studyType":23,"phases":511,"briefSummary":512,"conditions":513,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":520,"locationsCount":92},"100498368","investigation-and-modulation-of-the-central-mu-opioid-mechanism-in-migraine-in-vivo-100498368","NCT05769348","Investigation and Modulation of the Central Mu-Opioid Mechanism in Migraine (in Vivo)","Inclusion Criteria:\n\n* Male or female, aged 18 to 65 (inclusive)\n* Patients must have Episodic migraines that started before the age of 50, and currently experience:\n\n  * Chronic migraine (ICHD-3-beta), headache occurring on 15 days\u002Fmonth for more than six months, which, on at least eight days\u002Fmonth, has the features of a migraine headache.\n  * Episodic migraine (low frequency), specifically those with headache occurring less than 8 days\u002Fmonth.\n* Willing to limit the introduction of new treatments and medications during the study period.\n\nExclusion Criteria:\n\n* Significantly greater pain in body sites other than the head\n* Active, untreated major concurrent systemic illness other than migraine\n\n  * Medical conditions that can impair health status independent of migraine (including cardiopulmonary disorders, malignancy, uncontrolled endocrine or allergies)\n  * Systemic rheumatic disorders (i.e., rheumatoid arthritis, systemic lupus erythematosus, gout, and fibromyalgia);\n* History or current evidence of a psychotic disorder (e.g., bipolar disorder, schizophrenia) or severe major depression, as evidenced by Beck Depression score of \\>30\\*\n* History of neurological disorder (e.g., epilepsy, stroke, neuropathy, neuropathic pain)\n* Medication overuse headache (ICHD-3), regular intake for ≥10 days per month of ergotamine, triptans, combination analgesics, or any combination thereof OR ≥15 days per month of simple analgesics (acetaminophen, aspirin, NSAID), for more than 3 months\n* Current use of opioid or dopaminergic drugs (or use within the last 3 months) or substance abuse (self-reported)\n* Drug test positive for opioid or recreational drug (e.g., cannabis) at the time of the PET scan visits\n* Allergic response to study radiotracers or chemically related drugs\n* Excluded by MRI Center or PET Center safety screening checklist (as administered by study staff)\n* Pregnant or lactating (negative urine pregnancy test must be available before any PET procedures are initiated)\n* Prior use of tDCS",{"count":52,"type":22},[54],"This study investigates whether unilateral and bilateral non-invasive brain stimulation, given for 20 minutes\u002Fonce per day for twenty days (M-F) can reduce migraine pain. Fourty patients will receive treatment (20 unilateral treatment, and 20 bilateral treatment), while twenty will receive a \"sham\" procedure. Another 20 Episodic Migraine patients will be recruited for the observational aim of the study which does not include brain stimulation.",[28],"2026-02-23",{"date":516,"type":33},"2026-02-25",{"date":518,"type":33},"2023-01-26",{"date":480,"type":22},{"name":521,"class":72},"University of Michigan",{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":528,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":530,"enrollmentInfo":531,"targetDuration":4,"studyType":23,"phases":532,"briefSummary":533,"conditions":534,"keywords":536,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":92},"100617067","embrace-study-enduring-migraine-benefit-from-responsive-artery-coil-embolization-100617067","NCT07313800","EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization","Enduring Migraine Benefit From Responsive Artery Coil Embolization (EMBRACE): A Single-Site, Non-Significant Risk Pilot Study of Middle Meningeal Artery Embolization Using FDA-Cleared Coils for Refractory Episodic Migraine","EMBRACE","Inclusion Criteria:\n\n* Age 18-60 years\n* Diagnosis of migraine (with or without aura)\n\n  -≥8 headache days per month\n* Failure of ≥2 preventive medication classes\n* Ability to complete electronic headache diary and surveys\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Secondary headache disorders\n* Prior MMA embolization\n* Contraindication to angiography or embolization\n* Pregnancy\n* Inability to comply with follow-up","60 Years",{"count":7,"type":22},[54],"This single-site, open-label pilot study evaluates the safety, feasibility, and potential durability of the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy targeting meningeal arterial contributors to migraine. Adults aged 18-60 with refractory migraine despite prior preventive therapies are eligible. The study assesses migraine outcomes over 12 months using patient-reported headache frequency, pain intensity, acute medication use, migraine-related disability (MIDAS), and quality-of-life measures (MSQ v2.1).",[111,535,28],"Refractory Migraine",[537,538,535,539,540,541,542,543,544,545],"Middle Meningeal Artery Embolization","MMA Embolization","Coil Embolization","Neurovascular Intervention","Migraine Prevention","TEMMA","TEMMA procedure","TEMMA protocol","Targeted Embolization for Migraine Management","2026-02-02",{"date":548,"type":33},"2026-02-04",{"date":550,"type":22},"2026-03-01",{"date":552,"type":22},"2028-03-01",{"name":554,"class":40},"Cortex Neurovascular",{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":225,"phases":4,"briefSummary":565,"conditions":566,"keywords":567,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":579,"locationsCount":360},"100508638","gepant-treatments-effectiveness-and-tolerability-gainer-100508638","NCT05903027","Gepant treAtments: EffectIveNess and tolERability (GAINER)","Effectiveness and Tolerability of Rimegepant as Acute Migraine Treatment: a Prospective, Multicentric, Cohort Study (GAINER)","GAINER","Inclusion Criteria:\n\n* Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III).\n* At least 3 MMDs\n* Good compliance to study procedures\n* Availability of headache diary at least of the preceding months before enrollment\n\nExclusion Criteria:\n\n* Subjects with contraindications for use of gepants;\n* Concomitant diagnosis of medical diseases and\u002For comorbidities that, in the Investigator's opinion might interfere with study assessments;\n* medical comorbidities that could interfere with study results;\n* Pregnancy and breastfeeding.",{"count":564,"type":22},100,"The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic migraine patients.",[110,112,113,28],[107,568,569,570,571],"Medication overuse headache","Pain","Gepant","Triptan","2026-01-19",{"date":574,"type":33},"2026-01-21",{"date":576,"type":33},"2023-06-15",{"date":578,"type":22},"2026-09-15",{"name":482,"class":72},{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":18,"minAge":588,"maxAge":4,"enrollmentInfo":589,"targetDuration":4,"studyType":23,"phases":590,"briefSummary":591,"conditions":592,"keywords":593,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":92},"100532967","laser-acupuncture-for-chronic-migraine-100532967","NCT06219694","Laser Acupuncture for Chronic Migraine","Enhancing Chronic Migraine Preventive Therapy: Laser Acupuncture as an Add-On Treatment for Patients With Unsatisfactory Pharmacological Effect, a Pilot Randomized Controlled Trial","LAFCM","Inclusion Criteria:\n\n* patients aged above 20 years old and had CM managed pharmacologically, including preventive and\u002For acute migraine medications, and in addition, those who had refused preventive agent despite recommendation of the neurologist;\n* patients who had unsatisfactory effect of current pharmacological treatments, defined as they self-reported\n* patients who had a minimum of one-year history of migraine with or without aura.\n\nExclusion Criteria:\n\n* patients who had received another LA therapy or traditional acupuncture at baseline\n* migraine onset after the age of 50\n* cognitive or psychological impairment interfering with the participant's ability to receive LA protocol and describe symptoms\n* patients with missing data at baseline or during the follow-up period.","20 Years",{"count":299,"type":22},[54],"A single-blind randomized controlled trial was conducted from October 2024 to May 2025. Chronic migraine patients were randomly assigned in a 1:1 ratio to receive either Laser acupuncture or sham treatment. The co-primary outcomes were changes in monthly migraine days (MMD) and acute headache medications usage days per month from baseline, and Hospital Anxiety and Depression Scale (HADS), and Beck's Depression Inventory(BDI) evaluation. Evaluations were taken at baseline and each follow-up point.\n\nAfter \\>6 months follow up as washing out time, the sham group received complementary laser acupuncture treatment and follow up for another 3 months, compared the Headache related parameters (onset, duration, pain scale, current medication for headache, menstrual cycle).",[28],[110,28,594,595],"laser acupuncture","Prevention","2025-11-17",{"date":598,"type":33},"2025-11-20",{"date":600,"type":33},"2022-01-01",{"date":602,"type":22},"2025-12-01",{"name":604,"class":72},"Taichung Veterans General Hospital",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":248,"enrollmentInfo":612,"targetDuration":4,"studyType":23,"phases":614,"briefSummary":615,"conditions":616,"keywords":617,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":627,"locationsCount":92},"100577251","acceptance-and-commitment-therapy-to-improve-disability-in-chronic-migraine-100577251","NCT06795867","Acceptance and Commitment Therapy to Improve Disability in Chronic Migraine","Does Acceptance and Commitment Therapy (ACT) Improve Disability in Chronic Migraine? A Randomized Headache Center Trial","Inclusion Criteria:\n\n* Willingness and ability to engage in the consent process\n* Willingness to participate in the study, despite randomization outcome\n* Availability for the duration of the study\n* Diagnosis of chronic migraine followed at the Graham Headache Center\n* Access to the necessary resources for participating in a technology-based intervention\n\nExclusion Criteria:\n\n* Known major depression or other psychiatric condition\n* Non-English speaking\n* Secondary headache diagnosis\n* Psychotherapy in the prior 18 months\n* Any reason the provider feels would limit participant ability to learn or practice ACT\n* Any previous experience with mindfulness or meditation approaches",{"count":613,"type":22},40,[54],"The goal of this clinical trial is to learn if the behavioral treatment called Acceptance and Commitment Therapy (ACT) works to improve disability in adults with chronic migraine. The main questions it aims to answer are:\n\nDoes the use of ACT added to usual treatment improve scores on questionnaires designed to measure daily functioning and activity? Does the use of ACT added to usual treatment improve scores on diaries designed to measure headache frequency and pain?\n\nResearchers will compare adding ACT to usual headache treatments to usual headache treatments without ACT.\n\nParticipants who are selected for ACT will take 8 classes to learn ACT and then will practice it at home, in addition to their regular headache treatment. Those not selected will continue their regular headache treatment. Four times over the following year, participants will answer questions about their symptoms during each of four virtual visits. They will also keep a daily headache diary during the study",[28],[116,618,619,620],"chronic migraine","behavioral management","acceptance and commitment therapy","2025-10-30",{"date":623,"type":33},"2025-10-31",{"date":625,"type":33},"2025-04-21",{"date":37,"type":22},{"name":628,"class":72},"Brigham and Women's Hospital",{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":633,"acronym":4,"eligibilityCriteria":634,"healthyVolunteers":49,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":635,"targetDuration":4,"studyType":225,"phases":4,"briefSummary":637,"conditions":638,"keywords":661,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":672,"startDateStruct":674,"completionDateStruct":676,"leadSponsor":678,"locationsCount":92},"100497203","assessing-symptom-and-mood-dynamics-in-pain-using-the-smartphone-application-soma-100497203","NCT05754190","Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA","INCLUSION CRITERIA \\[General study\\]\n\n* Chronic pain group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of greater than 3 in the past week or\n  * Average pain interference score of greater than 3 in the past week or\n  * Average pain distress score of greater than 3 in the past week\n  * Pain duration: greater than 6 months\n* Acute pain group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of greater than 3 in the past week\n\n    ○ or\n  * Average pain interference score of greater than 3 in the past week\n\n    ○ or\n  * Average pain distress score of greater than 3 in the past week\n  * Pain duration: less than 3 months\n  * Pain cause: Due to recent surgery, injury, acute illness, or childbirth (within the past 3 months)\n* Healthy control group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of less than 3 in the past week\n  * Average pain interference score of less than 3 in the past week\n  * Average pain distress score of less than 3 in the past week\n  * No surgery, injury, acute illness, or childbirth (within the past 3 months)\n* In person EEG testing \\[Sub-Study only\\]:\n\n  * Same as in General App Study Above and additionally:\n  * Current diagnosis of Fibromyalgia, Chronic Low Back Pain or Failed Back Surgery Syndrome OR\n  * No current or prior history of chronic pain\n  * If participant has chronic low back pain or failed back surgery syndrome: are they planning to have either a radio-frequency ablation, back surgery, or spinal cord stimulation implant in the next few months\n  * If participant has chronic low back pain or failed back surgery syndrome: have they received insurance approval for the procedure?\n  * Ok with EEC\u002FECG measures\n\nEXCLUSION CRITERIA \\[General study\\]\n\n* Chronic pain group:\n\n  * recent injury or surgery unrelated to the pain in the past 3 months\n  * difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n  * Not fluent in English (difficulty understanding questions)\n  * Current primary or metastatic cancer (organic cause of pain)\n* Acute pain group:\n\n  * History of Chronic Pain (Pain lasting for more than 6 months)\n  * difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n  * Not fluent in English (difficulty understanding questions)\n  * Current primary or metastatic cancer (organic cause of pain)\n* Healthy control group:\n\nHistory of Chronic Pain (Pain lasting for more than 6 months)\n\n* difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n* Not fluent in English (difficulty understanding questions)\n\n  -In person EEG testing \\[Sub-study only\\]: \\[will interfere with EEG data collection safety or quality\\]:\n* Same as in General App Study Above and additionally:\n* Baldness\n* Pregnancy\n* Dreadlocks\n* Left-handedness\n* Use of a wheelchair\n* Heart failure diagnosis\n* Current or prior experience with acute psychosis or mania\n* implanted pacemaker, neurostimulator or any other head or heart implants\n* require a hearing aid to hear properly\n* claustrophobia\n* metal fragments in the body",{"count":636,"type":22},800,"This study relies on the use of a smartphone application (SOMA) that the investigators developed for tracking daily mood, pain, and activity status in acute pain, chronic pain, and healthy controls over four months.The primary goal of the study is to use fluctuations in daily self-reported symptoms to identify computational predictors of acute-chronic pain transition, pain recovery, and\u002For chronic pain maintenance or flareups. The general study will include anyone with current acute or chronic pain, while a smaller sub-study will use a subset of patients from the chronic pain group who have been diagnosed with chronic low back pain, failed back surgery syndrome, or fibromyalgia. These sub-study participants will first take part in one in-person EEG testing session while completing simple interoception and reinforcement learning tasks and then begin daily use of the SOMA app. Electrophysiologic and behavioral data from the EEG testing session will be used to determine predictors of treatment response in the sub-study.",[639,640,641,642,643,644,645,646,28,647,648,649,650,651,652,653,654,655,656,657,658,659,660],"Chronic Pain","Acute Pain","Post Operative Pain","Fibromyalgia, Primary","Fibromyalgia, Secondary","Fibromyalgia","Irritable Bowel Syndrome","Chronic Headache Disorder","Chronic Pelvic Pain Syndrome","Temporomandibular Joint Disorders","Endometriosis-related Pain","Arthritis","Chronic Low-back Pain","Failed Back Surgery Syndrome","Post Herpetic Neuralgia","Neuropathic Pain","Painful Diabetic Neuropathy","Painful Bladder Syndrome","Trauma-related Wound","Trauma, Multiple","Chronic Pain Syndrome","Chronic Shoulder Pain",[662,663,664,665,666,667,668,669,670],"digital health","e-health","smartphone application","chronic pain","acute pain","symptom tracking","experience sampling methodology","ecological momentary assessment","pain self-management","2025-09-16",{"date":673,"type":33},"2025-09-19",{"date":675,"type":33},"2023-06-20",{"date":677,"type":22},"2026-05-30",{"name":679,"class":72},"Brown University"]